Select the image to view the label in detail.
CJC-1295 With DAC research profile
What is being studied?
CJC-1295 with DAC is a modified hGRF(1-29) analogue designed to bind serum albumin through an added reactive group, extending stability relative to unmodified GHRH fragments.
Published work characterised albumin conjugation, rat pituitary-cell bioactivity and growth-hormone secretory patterns. Results depend on the species, model and exposure design.
Research areas
- Albumin-conjugation and peptide-stability assays
- GHRH-receptor and pituitary-cell response models
- DAC versus no-DAC analogue comparisons
Selected studies
How to read this research
These papers study defined compounds in specific experimental systems or clinical trials. They do not test or certify this product, its batch or its prepared presentation. Component and related-peptide studies do not establish the effects of a finished blend. Findings are research context, not evidence of safety or suitability for personal use. For laboratory research only; no treatment, dosing or use advice is provided.
CJC-1295 With DAC research record
Molecular identity and stated sequence or composition, alongside the batch, storage, dispatch and document record for this 10-vial case.
Molecular identity
Albumin-binding hGRF(1-29) analogue
Sequence / composition
Tetrasubstituted hGRF(1-29) analogue with a reactive albumin-binding group
Product record
The listing identifies the presentation, specification, storage record, dispatch status, and batch-document availability for the relevant product or batch.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.